HEALTHJun 30 · 07:05 UTCSTAT NEWSAndrew Joseph

STAT+: Abivax seeks to ease safety concerns with new data, boosting shares

Abivax released additional data on its experimental ulcerative colitis drug obefazimod to address safety concerns, leading to a 25% rise in U.S.-listed shares. The drug showed strong efficacy in a maintenance trial, but prior cancer cases among participants had raised safety risks.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AbivaxorganizationFranceplaceobefazimodtopiculcerative colitistopiccancertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 1 · 21:31 UTC
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
HEALTHJun 30 · 08:05 UTC
French biotech stock soars 31% after new data on experimental medicine
BUSINESSJan 24 · 16:52 UTC
Novo Nordisk Shares Surge on New Obesity Drug Results
BUSINESSJun 8 · 09:40 UTC
Weight loss drug maker sinks 25% after new safety data spooks investors
HEALTHJun 2 · 15:04 UTC
STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
HEALTHJun 1 · 10:49 UTC
Akeso lung cancer drug shines in trials, boosting hopes in US$20b market